Evidence map›Paper›PMID 42477141›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Undifferentiated embryonal sarcoma of the liver with a novel MAD1L1::ERG fusion: a 20-year survival case report.

Mei Yang, Zunguo Du, Feng Tang, Jie Fan, Xiaomu Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mei YangHuashan Hospital, Fudan University, Shanghai, China.
Zunguo DuHuashan Hospital, Fudan University, Shanghai, China.
Feng TangHuashan Hospital, Fudan University, Shanghai, China.
Jie FanHuashan Hospital, Fudan University, Shanghai, China.
Xiaomu HuHuashan Hospital, Fudan University, Shanghai, China. Huxm1993@163.com.

Funding

Natural Science Foundation of Shanghai 25ZR1401037Shanghai Action Plan for Science Technology and Innovation 2023DFYCQN02
6 · The paper itself

Abstract

Undifferentiated embryonal sarcoma of the liver (UESL) is a rare, highly aggressive malignant mesenchymal tumor that predominantly affects children and typically carries a poor prognosis. We report a unique UESL case with long-term survival harboring a novel MAD1L1::ERG gene fusion. A 15-year-old female underwent segmentectomy for a 15-cm hepatic mass, without a precise diagnosis initially. From 2018 to 2025, she experienced multiple recurrences involving the liver, right kidney, and retroperitoneum. Histopathological examination across all recurrences consistently showed classic UESL features: pleomorphic spindle or polygonal cells in a myxoid stroma, frequent mitotic figures, bizarre multinucleated giant cells, and characteristic PAS-positive eosinophilic hyaline globules. Immunohistochemistry (IHC) was positive for vimentin. Targeted DNA next-generation sequencing (NGS) identified 23 genetic alterations, most notably a novel MAD1L1::ERG gene fusion (breakpoint: MAD1L1 Intron 18 and ERG Exon 13) alongside CCND2, FGFR3, MYC, SRC amplifications, and a TP53 mutation. Despite the tumor's highly aggressive behavior, the patient achieved long-term survival through repeated multi-visceral resections and systemic chemotherapy (VAC and IE). This report expands the molecular genetic profile of UESL by identifying a previously undescribed gene rearrangement.

Indexed as

MAD1L1:ERG fusionMolecular profilingUndifferentiated embryonal sarcoma of the liver (UESL)

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.